

CVC Working Group Meeting Minutes

December 3, 2020

1:30-2:30pm EST

No.	Description	Notes
1	COVID-19 trade name concepts	<ul style="list-style-type: none"> ● Linda Parisien (Canada Health Infoway) and Dr. Robert Pless (Health Canada) will work together to fill in existing RFCs for trade name concepts for the Pfizer and Moderna vaccines and will aim to have these completed by next week. ● P/Ts reached consensus that acquiring codes for COVID-19 vaccine trade name products is the most urgent priority in the interim. ● P/Ts indicated that changing the trade name/fully specified name when more product information becomes available is acceptable as long as codes are available and remain the same.
2	COVID-19 generic concepts	<ul style="list-style-type: none"> ● These high-level generic concepts will be included in the next CVC release: <ul style="list-style-type: none"> ○ 28531000087107 Vaccine product against disease caused by Severe acute respiratory syndrome coronavirus 2 (medicinal product) ○ 1119349007 Vaccine product containing only Severe acute respiratory syndrome coronavirus 2 messenger ribonucleic acid (medicinal product) ● Further discussion is needed on whether to include the below concept: <ul style="list-style-type: none"> ○ 1119305005 Vaccine product containing only Severe acute respiratory syndrome coronavirus 2 antigen (medicinal product)
3	COVID-19 abbreviations	<ul style="list-style-type: none"> ● The generic agent abbreviation listed on the NACI website is COVID-19 and will be used in the interim. This will not be confirmed until the vaccine is approved. ● Further discussion is required on what values should be used for generic abbreviations and whether these values must uniquely identify the trade name product. The CVC team's opinion is that this should not be a requirement as this has not been what was done for other vaccines, and that the CVC clinician picklist term or preferred term should be used when implementing a vaccine picklist for the administered vaccine use case. We do not have visibility into Panorama however and understand that the requirement might be driven by how Panorama's picklists are implemented. We will continue this discussion in our next meeting.
4	Dissemination of codes	<ul style="list-style-type: none"> ● As soon as we receive codes from Canada Health Infoway, the CANImmunize team will send out this information to

		<p>P/Ts in the group via email, linking them to the RFCs in Informs.</p> <ul style="list-style-type: none"> • This will also be posted in the Public Health Surveillance community forum on InfoCentral. This is a public and open group that can be accessed by anyone.
5	Next meeting	<ul style="list-style-type: none"> • The next working group meeting on this topic will be scheduled for Wednesday, December 9th from 12:00-1:00pm EST. Please register in advance for this meeting via the following link: https://infoway-inforoute.zoom.us/meeting/register/tJwud-GogzouGNJH2DbXKQBaUx-9r2Yv-vuP. After registering, you will receive a confirmation email containing information about joining the meeting. • Meeting information will be posted in the Public Health Surveillance community as well. Please see the instructions below to join this community.
6	Join PHS Community on InfoCentral	<p>If stakeholders have not already, we encourage them to join the Public Health Surveillance community on InfoCentral to engage and stay up to date with the work of the CVC and similar discussions.</p> <ul style="list-style-type: none"> • Step 1: Register for an Infoway Account and follow the instructions to create an account if you do not have one. If you have an existing account, log in. • Step 2: Once you have registered and/or are logged in, visit the Public Health Surveillance community page and click "Join the group" at the top of the home page. • By default, once you join the Public Health Surveillance Community, you will receive an email for each new topic on the forum. You can change your notification settings at any time.